Table 1.
Baseline Demographics, Clinical, and Laboratory Data (n = 102)
| Male, n (%) | 64 (62.8) |
| Age at PSC diagnosis, mean ± SD (range), y | 31.4 ± 14.2 (11–86) |
| Age at IBD diagnosis, mean ± SD (range), y | 26.0 ± 12.3 (9–62) |
| Cirrhosis, n (%) | 21 (20.6) |
| Type of PSC, n (%) | |
| Large-duct PSC | 92 (90.2) |
| Small-duct PSC | 8 (7.8) |
| PSC/AIH overlap | 2 (2.0) |
| Type of IBD, n (%) | |
| Ulcerative colitis | 66 (64.7) |
| Crohn’s disease | 30 (29.4) |
| IBD-unspecified | 6 (5.9) |
| UDCA use, n (%) | 61 (59.8) |
| Mean dose ± SD (range), mg/kg/day | 13.9 ± 3.7 (5–20.4) |
| Previous anti-TNF use, n (%) | 66 (64.7) |
| Duration of vedolizumab, median (range), d | 412 (37–2609) |
| ALP >ULN at baseline, n (%) | 69 (67.7) |
| Baseline laboratory tests, median (IQR) | |
| Alkaline phosphatase (IU/L × ULN) | 1.54 (0.86–2.67) |
| Alanine transaminase (IU/L) | 38 (22–76) |
| Aspartate transaminase (IU/L) | 38 (23–69) |
| Bilirubin (μmol/L) | 10 (6.6–16.0) |
| Albumin (g/L) | 37 (33–41) |
| Platelets (x106/L) | 330 (213–401) |
| International normalized ratio | 1 (0.97–1.12) |
| Creatinine (μmol/L) | 70 (63–80) |
| Sodium (μmol/L) | 139 (137–141) |
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; IBD, inflammatory bowel disease; IQR, interquartile range; PSC, primary sclerosing cholangitis; SD, standard deviation; TNF, tumor necrosis alpha; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.